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Lipid raftsnt natural target cell for HIV-1, but previous studies of virus entry into these cells
are limited, and the involvement of membrane cholesterol and lipid rafts is unknown. Cholesterol disruption
of macrophage membranes using four pharmacological agents acting by different mechanisms: methyl-β
cyclodextrin, nystatin, ﬁlipin complex and Lovastatin, all signiﬁcantly inhibited productive HIV entry and
reverse transcription. The inhibitory effects of these drugs resulted in decreased virus release from infected
cells, and could be substantially reversed by the addition of water-soluble cholesterol. The virus bound
equally to cholesterol-disrupted cells even though HIV receptor expression levels were signiﬁcantly reduced.
Macrophage CD4 and CCR5 were found to partition with the detergent-resistant membranes with a typical
raft-associating protein ﬂotillin-1. HIV particles were observed co-localising with a marker of lipid rafts (CTB-
FITC) early post infection. These data suggest that macrophage membrane cholesterol is essential for HIV
entry, and implicate lipid raft involvement.
© 2009 Elsevier Inc. All rights reserved.Introduction
Virus entry into target cells is a complex process involving many
cellular and viral proteins with the primary goal of overcoming the
barrier of the cellular membrane. Some viruses achieve this by
acquiring a lipid envelope during exit from the host cell; these
enveloped viruses enter cells by fusion of their envelope with the
cellular membrane at either the cell surface or within an endosome.
Viruses without a lipid envelope have acquired mechanisms to
penetrate the membrane barrier, entering cells mainly via an
endocytic pathway using either clathrin-coated vesicles or caveolae,
or by the formation of a pore at the cell surface as has been proposed
for poliovirus (Hogle, 2002; Marsh and Helenius, 2006; Smith and
Helenius, 2004). There is a growing amount of evidence that
cholesterol, an important structural component that modulates the
ﬂuidity of biological membranes, is essential for the uptake of many
viruses. Successful virus entry may require cholesterol in the host cell
membrane or in the viral envelope. Many enveloped viruses, such as
vaccinia virus (Chung et al., 2005), herpes simplex virus (Bender et al.,
2003) and severe acute respiratory syndrome-coronavirus (Li et al.,
2007) require cholesterol in the target cell membrane. The same is
true for many non-enveloped viruses; SV40 (Anderson et al., 1996),
foot-and-mouse disease virus and echovirus (Marjomaki et al., 2002;
Pietiainen et al., 2004) require cholesterol to enter cells by the lipid
raft-dependent caveolae endocytosis pathway. In the case of inﬂuenza
virus, the presence of cholesterol in its viral envelope is critical, but ites).
l rights reserved.is not essential in the target cell (Sun and Whittaker, 2003), whereas
the converse has been found for murine leukaemia virus (Lu and
Silver, 2000) and duck hepatitis B virus (Funk et al., 2008). In contrast,
various strains of dengue virus and yellow fever virus enter and infect
cells independently of cholesterol (Umashankar et al., 2008).
Cholesterol is concentrated within the ﬂuid mosaic bilayer of the
plasma membrane, along with sphingolipids and glycerophospholi-
pids, in specialised dynamic microdomains known as lipid rafts. These
lipid assemblies are tightly packaged and ordered, allowing them to
ﬂoat within the rest of the ﬂuid sea of disordered lipid bilayer (Simons
and Ikonen,1997). The presence of cholesterol in the lipid rafts confers
some resistance to detergents at low temperatures, allowing their
separation from detergent-sensitive membranes by ultracentrifuga-
tion (Wilﬂingseder and Stoiber, 2007). Due to this property, they are
often referred to as detergent-resistant membranes (DRMs). Mem-
brane rafts act as mobile platforms within the plasma membrane, and
are involved in many important diverse cellular processes. Many
proteins associate with lipid rafts, and these include GPI-anchored
proteins, GTPases and kinases. Mounting evidence for the cholesterol
dependency of productive virus entry suggests that many viruses may
hijack these dynamic lipid raft platforms to utilise them as an entry
portal to the cell.
Cholesterol is already known to be important at multiple stages of
the HIV lifecycle. The virus assembles and buds out of lipid raft
domains, and in doing so acquires a cholesterol and sphingomyelin-
rich envelope (Aloia et al., 1988, 1993; Campbell et al., 2004) that is
resistant to detergents but has a strikingly different composition to
host cell membranes (Brugger et al., 2006; Chan et al., 2008). The HIV
accessory protein, Nef, functions onmany levels tomanipulate cellular
cholesterol, including binding to cholesterol to enhance its trafﬁcking
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esis (van 't Wout et al., 2005) and inhibiting cholesterol efﬂux by
redistributing a major component of the cholesterol efﬂux pathway
(Bukrinsky and Sviridov, 2006; Castrillo et al., 2003). Although in
contrast, other studies have found that Nef speciﬁcally enhances the
incorporation of sphingomyelin but not cholesterol into budding viral
particles (Brugger et al., 2007). The importance of HIV envelope lipid
composition is highlighted by the ﬁnding that depletion of viral
envelope cholesterol causes a dramatic reduction in viral infectivity
(Brugger et al., 2006; Campbell et al., 2004, 2002; Guyader et al., 2002;
Liao et al., 2003).
The early events in HIV entry, in which the viral envelope protein,
gp120–gp 41, engages with the primary receptor CD4 on target cells,
are well characterised. This interaction permits conformational
changes within gp120 that allow additional binding to a co-receptor,
usually CXCR4 for T-lymphocyte tropic strains, or CCR5 for macro-
phage tropic isolates. Co-receptor binding is the trigger for virus entry,
during which the fusion peptide gp41, inserts into the cellular
membrane to drive the fusion event. The lipid composition of the
host cell is important for HIV entry. Cholesterol depletion of target
cells using pharmacological agents prevents HIV entry, and render
cells resistant to infection (Kozak et al., 2002; Liao et al., 2001; Nguyen
and Taub, 2002b; Popik et al., 2002). The association of CD4 with lipid
raft domains is well accepted (Kozak et al., 2002; Nguyen et al., 2005;
Percherancier et al., 2003; Popik et al., 2002), but whether this
association is required to support productive virus entry is disputed.
One study found that mutant CD4 targeted to non-raft membranes did
not permit efﬁcient HIV entry (Del Real et al., 2002), whereas
alternative CD4 mutants that also prevent CD4 association with lipid
rafts were found to support HIV entry (Percherancier et al., 2003;
Popik and Alce, 2004). The membrane localisation of the co-receptor
molecules is somewhat controversial. CCR5 has been shown to
associate with lipid rafts microdomains in cell lines by its presence
in DRM fractions and its co-localisation with the raft associated lipid
GM1 (Manes et al., 1999; Popik et al., 2002). In contrast, studies in
primary T cells identiﬁed CCR5 in the detergent-soluble membrane
(DSM) fractions representing the non-raft membranes (Percherancier
et al., 2003). CXCR4 has been reported to be lipid raft-associated in 293
cells (Manes et al., 2000) but non-raft-associated in T cell lines (Kozak
et al., 2002; Popik et al., 2002). HIV-1 gp120 binding to CD4molecules
in lipid rafts has been proposed to cause recruitment of the HIV co-
receptor into the lipid rafts or its interface, thus bringing all molecules
required for HIV entry together (Kozak et al., 2002; Nguyen et al.,
2005; Popik et al., 2002).
A different productive entry pathway for HIV into macrophages
has been described, in which virus is taken up by an endocytic route
involving macropinocytosis, a constitutive process whereby the cell
takes up large quantities of the extracellular ﬂuid (Marechal et al.,
2001). Numerous intracellular pathogens are taken up into macro-
phages by macropinocytosis, including Brucella (Watarai et al., 2002)
and Aﬁpia felis (Schneider et al., 2007), and in these cases a
requirement for lipid rafts has been established. Cholesterol is already
known to play an important role in HIV replication of macrophages,
with speciﬁc studies showing that Nef affects the normal function of
ATP-binding cassette transporter A1 to impair cholesterol efﬂux from
infected macrophages (Mujawar et al., 2006). Modulation of intracel-
lular lipid metabolism in HIV-infected macrophages may facilitate
virus budding from lipid raft associated membranes, but it is tempting
to infer that cholesterol might also play an important role in the entry
of HIV into macrophages.
All of the studies regarding the involvement of cholesterol and
lipid rafts in HIV entry have been performed using immortalised cell
lines, T cell lines and primary CD4+ lymphocytes. Given their critical
position in HIV pathogenesis, and their highly specialized cellular
architecture, we thought it necessary to investigate the requirement of
cholesterol and role of lipid rafts in HIV-1 entry into macrophages. Wehave assessed the effect of depleting cholesterol in the macrophage
plasma membrane, using four different pharmacological agents, on
virus binding, entry and HIV receptor levels. Here we show that
membrane cholesterol is essential for productive HIV entry into
macrophages. Virus binding to cholesterol-depleted macrophages is
not reduced but there are alterations to the surface expression of the
receptor molecules. We observed virus co-localising with a marker of
lipid rafts early after infection, and isolatedmacrophage CD4 and CCR5
in the membrane fractions representing raft microdomains. This,
together with the sensitivity of virus entry to membrane cholesterol
depletion, implies a role for macrophage lipid rafts in HIV-1 entry.
Results
HIV co-localises with markers of lipid rafts
To investigate the involvement of lipid rafts in HIV uptake into
macrophages, we ﬁrst sought to visualise virus entry and lipid rafts
using ﬂuorescent Cholera toxin B subunit (CTB-FITC) the binding of
which to GM1 clusters these membrane domains together into larger
patches that can be observed microscopically. HIV NL4.3 pseudotyped
with JRFL envelope was bound to macrophages on ice, and warmed to
37 °C in the presence of CTB-FITC and analysed at various times post
entry. A representative experiment taken at 20 min post entry is
shown in Figs. 1A–D, and shows virus co-localising with CTB-positive
areas of the macrophage plasma membrane. The number of particles
directly associated with GM1-positive membranes on the cell surface
or in endocytic vesicles was quantiﬁed by taking 0.8 μm Z-slices
through the cell and scoring the percentage of the total particles co-
localising with CTB-FITC. Three consecutive Z-slice focal planes are
shown in panels A–C. These slices start towards the bottom of the cell
(A) and proceed upwards, and show many cell-associated virus
particles clearly co-localising with CTB-FITC. The distribution of all
virus particles and CTB-FITC is shown in a projection of Z-stack slices
in panel D. Analysis of multiple cells (n=10) at 20 min post entry
shows approximately 34% (±3.72 SEM) of total particles are co-
localising with CTB-FITC. At later times post entry (40 and 60 min),
there is a reduction in association of virus with CTB-FITC perhaps due
to productive entry of most virus particles into the cytoplasm or
degradation of the virus preventing its detection (Fig. 1E).
Cholesterol depletion of macrophages inhibits HIV entry but not binding
Membrane cholesterol can be disrupted by a number of pharma-
cological agents; the manipulation of this key component of lipid
microdomains is frequently used to implicate these assemblies in
virus entry. The effects of methyl-β cyclodextrin (MβCD) are well
characterised. This cholesterol-binding agent is not incorporated into
the membrane but selectively extracts membrane cholesterol by
binding it in a central non-polar cavity (Ilangumaran and Hoessli,
1998). We incubated macrophages with various concentrations of
MβCD in serum-free media, and measured the depletion of lipid rafts
by detecting ﬂuorescent CTB-FITC binding to the raft glycolipid GM1
by ﬂow cytometry. CTB-FITC binding to drug-treated cells on ice was
reduced in a dose-dependent manner compared to untreated cells
conﬁrming that MβCD effectively disrupts macrophage lipid rafts (Fig.
2A). The effect of this drug on cell viability was measured using the
MTS cytotoxicity assay (Fig. 2B) and showed that 1 h treatment with
MβCD had no toxic effect on the macrophages. Quantiﬁcation of the
amount of free cholesterol and cholesteryl esters in 10 mM MβCD-
treated macrophages using Amplex Red cholesterol quantiﬁcation
assay revealed a signiﬁcant decrease (p=0.01 by paired t-test) in all 6
donors tested with an average of 28.7% (±20.4%) reduction compared
to untreated control cells.
The potential anti-viral properties of MβCD on HIV entry into
macrophages was tested by measuring virus reverse transcription in
Fig. 1. Co-localisation of HIV with CTB-FITC. Replication-defective HIV generated by the transfection of 293T cells with pNL4.3luc R-E- and pJRFL envelope was spinoculated at 4 °C
onto macrophage monolayers on coverslips. Cells were incubated at 37 °C for 20 min to allow absorbed virus to enter cells in the presence of 10 μg/mL of CTB-FITC. Lipid rafts were
visualised by virtue of CTB-FITC ﬂuorescence and HIV particles were detected by labelling with anti-p17 mAb. Z stack analysis was performed on random cells; three consecutive
images (A–C) from the Z stack are shownwith panel A towards the bottom of the cell and panel C nearer the top of the cell, panel D is a projection of all Z stack images. The perimeter
of the cell is outlined and scale bar represents 20 μM. (E) The number of virus particles co-localising with CTB-FITC at 20, 40 and 60 min after binding was quantiﬁed by detailed Z-
stack analysis on 10 random cells for each time point. The total number of virions per cell was counted and then the % virions associating with CTB-FITC was determined. Error bars
represent mean±SD.
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during budding, and MβCD can deplete this virion cholesterol,
resulting in reduced virus infectivity (Guyader et al., 2002; Liao et
al., 2003). Therefore, to avoid this potentially confounding effect, cells
were pre-treated with MβCD for 1 h, and washed extensively before
the addition of virus, to ensure that any anti-viral effects observed
were not due to decreased particle infectivity. MβCD treatment of
macrophages was found to signiﬁcantly reduce the generation of
reverse transcription products following challenge with HIV BaL, at
both concentrations tested, in macrophages derived from six different
donors (Fig. 2C). The inhibitory effect of MβCD could be partially
reversed by the replenishment of cellular cholesterol with water-
soluble cholesterol added for 1 h directly after MβCD treatment.
Cholesterol replenishment restored virus reverse transcription to
43.5% of the untreated control (Fig. 2D). The inhibitory effects of MβCD
were also observed when p24 release from infected cells was
measured by ELISA (Fig. 2E). Reduced p24 release kinetics were
observed in the early days post infection for all donors treated with
MβCD, but the effects were less pronounced due to the longer length
of this experiment and the measurement of multiple rounds of
infection. Restoration of p24 release kinetics was observed upon
cholesterol replenishment. Therefore, depletion of macrophage
membrane cholesterol with MβCD severely inhibits the early steps
of productive HIV infection of macrophages.
To further pinpoint the stage at which cholesterol-containing lipid
rafts are required in HIV infection, we determined the effect of
cholesterol depletion on virus binding to macrophages. Equal
amounts of HIV BaL were added to untreated and MβCD-treated
macrophages for 2 h on ice. Unbound virions were removed byextensive washing before cells were lysed and the amount of cell-
associated virus determined by p24 ELISA (Fig. 2F). A slight decrease in
virus adsorption to MβCD-treated macrophages compared to
untreated control cells was observed. However, this decrease was
not signiﬁcant and would not account for the 8-fold decrease
observed in reverse transcription in MβCD-treated cells. Therefore,
cholesterol and lipid rafts might play a minor role in virus binding but
they are more likely to be required for entry or post-entry events.
Cholesterol depletion alters HIV receptor surface expression
Decreased entry of HIV might be attributed to alterations in
receptor or co-receptor levels; therefore we sought to determine if
MβCD treatment of macrophages alters the levels of CD4, CCR5 and
CXCR4. Detection of these cell surface molecules using antibody
labelling followed by ﬂow cytometry shows that control macrophages
express CD4, CCR5 and CXCR4 at detectable levels (Fig. 3A). Treatment
of macrophages with MβCD signiﬁcantly decreases the cell surface
expression of all receptors; CD4 by 35%, CCR5 by 100% and CXCR4 by
59%. Both CCR5 and CXCR4 expression levels are restored upon
cholesterol replenishment, implying that the decrease is due solely to
cholesterol depletion. Interestingly, replenishment with cholesterol
does not restore the CD4 expression levels, but reduces them further
to almost undetectable levels. This further reduction in CD4 expres-
sion may explain why cholesterol replenishment only partially
restores HIV reverse transcription (see above). MβCD treatment of
macrophages does not reduce the expression of all membrane
proteins because the expression of CD71 (transferrin receptor), a
known non-raft associated protein, was not reduced. Therefore, MβCD
Fig. 2. Depletion of cholesterol byMβCD inhibits HIV infection of macrophages. (A) Depletion of macrophage lipid rafts wasmeasured by detecting CTB-FITC binding toMβCD treated
cells. CTB binding occurred for 30 min on ice and was measured by ﬂow cytometry where cellular autoﬂuorescence (without CTB-FITC) was used as the control. (B) Cell viability after
1 h treatment with MβCD was determined using the MTS cytotoxicity assay with the number of viable cells being expressed as a % of untreated control cells. (C) Productive HIV entry
into MβCD treated macrophages was measured by detecting virus reverse transcription products by qPCR after 30 h of infection. The number of copies of HIV-1 DNAwas normalised
to the number of cells using a β-actin control. (D) MβCD treated macrophages were treated with 400 μg/mL of water-soluble cholesterol for 1 h before HIV BaL infection. After 30 h,
productive HIV entry was measured by qPCR as before. (E) HIV-1 infection following MβCD treatment and cholesterol replenishment was measured by detecting released virus in
supernatant samples (collected regularly from 1–15 days p.i.) by p24 ELISA. (F) Binding of HIV BaL to MβCD treated macrophages for 2 h on ice was measured by determining the
amount of cell-associated virus using p24 ELISA. Data represent mean±SD of results obtained with multiple independent experiments using several donors (4 donors for CTB,
viability and HIV binding assays, 4–6 donors for qPCR and p24 data is representative of 3 donors). ⁎⁎ Very signiﬁcant difference, pb0.01 and ⁎⁎⁎ extremely signiﬁcant difference
pb0.001 (paired t-test).
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rich lipid raft membranes without effecting non-raft associated
proteins. The combined decrease in CD4 and CCR5 receptor levels
may account for the decrease in productive HIV entry.
HIV receptors are associated with lipid rafts in macrophages
The reduction in HIV receptor levels in cholesterol-depleted
macrophages and the co-localisation of virus with a marker of lipid
rafts may imply that the receptors are localised in these micro-
domains. Traditional methods to isolate lipid rafts rely on cholester-
ol's property of favouring the formation of membranes that are
resistant to detergent at low temperature, and can be separated from
soluble membranes by ultracentrifugation. We adapted a procedurefor isolating macrophage DRMs by disrupting cells by a combination
of nitrogen cavitation and homogenisation followed by fractionation
using an Optiprep density gradient. Western blot analysis of equal
volumes of each fraction shows the expected localisation of the
control proteins: ﬂotillin-1 is located in fractions 4 and 5 represent-
ing the DRMs, and transferrin receptor is in fractions 8 and 9
indicative of the DSMs (Fig. 3B). The receptor CD4 is present in the
detergent-resistant fractions 4 and 5, and has a similar distribution
to that of ﬂotillin-1, although it is also present at low levels in
fractions 6 and 7. CCR5 is present in detergent-resistant fractions 4–5
only. Therefore, the receptors required for macrophage-tropic HIV
entry reside in the DRM fractions of macrophage membranes, which
have properties of lipid rafts and contain raft-associated protein
ﬂotillin-1.
Fig. 3.HIV receptors are associatedwith DRMs inmacrophages and their levels are altered byMβCD treatment.(A) The surface expression of HIV receptors afterMβCD and cholesterol
treatment was determined by staining macrophages with ﬂuorescent monoclonal anti-human antibodies to CD4, CCR5, CXCR4, CD71, or an appropriate isotype control. Cell surface
binding was measured by ﬂow cytometry, and mean ﬂuorescence intensity values were calculated by subtracting the isotype control ﬂuorescence from the speciﬁc antibody
ﬂuorescence. Representative FACS plots of macrophages from one donor are shown, and graphs show mean±SD of data acquired from ﬁve different donors. ⁎ Signiﬁcant difference
pb0.05, ⁎⁎ very signiﬁcant difference, pb0.01 and ⁎⁎⁎ extremely signiﬁcant difference pb0.001 (paired t-test). (B) Macrophage membranes from lysed cells were incubated in 1%
Triton X-100 and then fractionated using an Optiprep step gradient by ultracentrifugation. Fractions were collected, concentrated by TCA precipitation and 20 μL samples of each
fraction were analysed by SDS-PAGE using antibodies to CD4, CCR5, ﬂotillin and CD71.
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To exclude any drug-speciﬁc effects of MβCD, we used two other
compounds that can bind to cholesterol and disrupt lipid rafts by
directly inserting into membranes and sequestering cholesterol into
complexes. Both nystatin and ﬁlipin complex, at concentrations
signiﬁcantly inhibiting CTB-FITC binding (Fig. 4A) and not compro-
mising cell viability (Fig. 4B), inhibited HIV infection in a dose-
dependent manner. Nystatin at concentrations of 66 and 50 μg/mL
signiﬁcantly reduced reverse transcription in infected cells by 8.4- and
4.1-fold respectively compared to those treated with the same
concentration of DMSO vehicle (Fig. 4C). Filipin complex signiﬁcantly
inhibited the number of HIV reverse transcripts by 3.2-fold comparedto the untreated control (Fig. 4D). Similarly, these inhibitory effects
can be observed as reduced p24 release kinetics at early time points
post infection (Fig. 4E). Both nystatin and ﬁlipin complex do not
reduce virus binding to macrophages (Fig. 4F). This supports the
ﬁndings obtained by MβCD treatment, implying that cholesterol and
lipid rafts are likely to be required for entry and/or post-entry events
and not binding.
Studies with MβCD indicate that the HIV receptors are sensitive to
cholesterol depletion so we sought to determine if receptor levels
would also be altered when cholesterol organisation is disrupted by
anothermechanism (Fig. 4G). Nystatin signiﬁcantly decreased CD4 and
CCR5 expression by 59% and 91%, respectively. The expression level of
CXCR4was only slightly decreased. However, nystatin did signiﬁcantly
Fig. 4. Nystatin and ﬁlipin complex inhibit HIV entry into macrophages. (A) CTB-FITC binding to nystatin and ﬁlipin treated cells for 30 min on ice was measured by ﬂow cytometry,
with cellular autoﬂuorescence (without CTB-FITC) used as the control. (B) Cell viability after 1 h treatment with nystatin or ﬁlipin was determined using the MTS cytotoxicity assay
with the number of viable cells being expressed as a % of untreated control cells. (C, D) Productive HIV entry into nystatin (C) or ﬁlipin complex (D) treatedmacrophages was detected
after 30 h of infectionwith HIV BaL by qPCR. (E) HIV-1 infection following nystatin and ﬁlipin complex treatmentwasmeasured by detecting released virus in supernatant samples by
p24 ELISA. (F) Binding of HIV BaL to nystatin (50 μg/mL) and ﬁlipin complex (5 μg/mL) treated macrophages for 2 h on ice was measured by p24 ELISA. (G) The surface expression of
HIV receptors after nystatin or ﬁlipin complex treatment was determined by staining macrophages with ﬂuorescent antibodies to CD4, CCR5, CXCR4, CD71 or an appropriate isotype
control. Cell surface binding was measured by ﬂow cytometry, and mean ﬂuorescence intensity values were calculated by subtracting the isotype control ﬂuorescence from the
speciﬁc antibody ﬂuorescence. Data represent mean±SD of results obtained with multiple independent experiments (3 donors for qPCR, CTB and p24 binding assays, 4 donors for
receptor expression, viability and p24 data is representative of at least 2 donors). ⁎ Signiﬁcant difference pb0.05, ⁎⁎ very signiﬁcant difference, pb0.01 (paired t-test).
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cell surface expression of many proteins including those outside lipid
rafts. Conversely, ﬁlipin complex marginally decreased CD4 and CCR5
but had no effect on the levels of CXCR4 or CD71. The anti-viral effects
of nystatinmight be explained by the lower levels of CD4 and CCR5 but
it is likely that ﬁlipin complex might inhibit infection by a different
mechanism than decreased receptor levels.
Inhibition of cholesterol synthesis inhibits HIV entry
The cholesterol-binding drugs, MβCD, nystatin and ﬁlipin,
mechanically disrupt lipid rafts either by actively removing or bysequestering cholesterol. Lipid rafts can also be disrupted using
statins, such as Lovastatin. These drugs inhibit the 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase enzyme respon-
sible for the production of mevalonate, a precursor in cholesterol
biosynthesis. Cells were treated with Lovastatin for 4 days in the
presence of serum-free medium supplemented with lipoprotein-
deﬁcient serum after which cell viability was unaffected (Fig. 5A). The
binding of CTB-FITC to Lovastatin-treated cells was reduced by 33%
(±11.1%) compared to the untreated cells (Fig. 5B). Lovastatin
treatment of macrophages very signiﬁcantly inhibited HIV reverse
transcription in a dose-dependent manner by 16.6- and 5-fold with
12.5 μM and 5 μM Lovastatin, respectively (Fig. 5C). A marked decrease
Fig. 5. Inhibiting cholesterol synthesis inhibits HIV entry into macrophages. (A) Cell viability after 4 days treatment with Lovastatin and/or mevalonate was determined by MTS
cytotoxicity assay with the number of viable cells being expressed as a % of untreated control cells. (B) CTB-FITC was bound to Lovastatin-treated macrophages for 30min at 37 °C and
was measured by ﬂow cytometry, with CTB-FITC binding on ice used as the control. (C) Productive HIV BaL entry into macrophages pre-treated with Lovastatin for 4 days was
measured after 30 h of infection by qPCR. (D) HIV-1 infection following Lovastatin treatment was measured by detecting released virus in supernatant samples by p24 ELISA. (E)
Macrophages were pre-treated with 12.5 μM Lovastatin and/or 800 μg/mL mevalonate (whose production is blocked by Lovastatin) for 4 days. Productive HIV entry was measured by
qPCR detection of HIV BaL reverse transcription after 30 h of infection. (F) The surface expression of HIV receptors after Lovastatin treatment was determined by staining
macrophages with ﬂuorescent antibodies to CD4, CCR5, CXCR4, CD71 or an appropriate isotype control. Data represent mean±SD of results obtained with multiple independent
experiments (2 donors for CTB and viability assays, 2–5 donors for qPCR, 5–6 donors for receptor expression and p24 data are representative for 2 donors). ⁎⁎⁎ Extremely signiﬁcant
difference pb0.001 (paired t-test).
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observed (Fig. 5D). The effects of Lovastatin on HIV reverse transcrip-
tion were partially reversed by the addition of mevalonate, the
product of HMG-CoA reductase, to the culture medium (Fig. 5E). The
surface expression levels of all HIV receptors (but not CD71) were
decreased after Lovastatin treatment but not to signiﬁcant levels (Fig.
5F). Although these effects consistently implicate normal cholesterol
synthesis for productive virus entry and receptor expression levels, we
were unable to detect signiﬁcant changes in cholesterol abundance
per se in Lovastatin-treated cells using the standard assay.Discussion
Here we have demonstrated the critical importance of cholesterol
for entry of HIV-1 into macrophages. Firstly, we showed that
productive virus entry is signiﬁcantly reduced when the macrophage
target cells are treated with MβCD, a cholesterol-depleting drug. By
incubating cells with this drug before the addition of virus, only
cholesterol from the target cells would be removed allowing virus
particle cholesterol and infectivity to remain intact. The addition of
exogenous cholesterol to macrophage membranes directly after
199G.C. Carter et al. / Virology 386 (2009) 192–202MβCD treatment substantially restored HIV infection, indicating that
the decreased infectivity was at least in part due to the depletion of
cholesterol from the cell membrane. Secondly, we modiﬁed the
properties of cholesterol-rich macrophage membranes using nystatin
and ﬁlipin complex to sequester cholesterol into large aggregates.
Treatment of macrophages with these drugs signiﬁcantly inhibited
productive HIV entry in a concentration-dependent manner. Thirdly,
depletion of macrophage cholesterol using Lovastatin, a compound
that inhibits HMG-CoA reductase, the rate limiting enzyme in
cholesterol biosynthesis, signiﬁcantly inhibited HIV productive entry
after a prolonged 4 day treatment. Incubation of macrophages with
mevalonate, whose production is prevented by Lovastatin, partially
restored productive HIV entry into macrophages. Therefore, modiﬁca-
tion of macrophage membrane cholesterol content using 4 different
pharmacological inhibitors acting on cholesterol by different mechan-
isms all signiﬁcantly inhibited HIV entry.
Cholesterol is a major component of lipid raft microdomains and
manipulation of its localisation or presence within membranes is
frequently used to implicate these lipid assemblies in virus entry. Here
we provide additional evidence for the involvement of macrophage
lipid raft microdomains in HIV-1 entry by observing virus co-
localisation with a marker (CTB-FITC) of these microdomains at an
early time post-infection. Furthermore, we have isolated the receptor
molecules CD4 and CCR5, the receptors typically utilised by macro-
phage-tropic viruses, in DRM fractions partitioning with a known-raft
associated protein ﬂotillin-1. These results conﬁrm observations
regarding the importance of target cell plasma membrane cholesterol
and lipid raft microdomains in virus entry into T cell lines and primary
CD4+ T cells (Liao et al., 2001; Manes et al., 2000; Percherancier et al.,
2003; Popik et al., 2002) and extend them to macrophages, a critical
natural target cell for HIV-1.
For viruses to infect target cells, they have to ﬁrstly bind to
attachment factors or receptor molecules on the cell surface. A
decrease in productive virus entry may reﬂect a reduction in virus
binding to cells. We conﬁrmed which stage of infection was being
affected by cholesterol depletion by investigating virus binding to the
macrophage membranes. No signiﬁcant decrease in the amount of
bound virus after a 2 h incubation on ice was observed between drug-
treated and control untreated macrophages. This indicates that
cholesterol depletion of macrophages does not perturb the attach-
ment of virus, perhaps to alternative molecules such as heparan
sulphate glycosaminoglycans (Saphire et al., 2001), but must alter
virus entry events after attachment.
The surface expression levels of the HIV receptors were found to
be altered to differing extents by the 4 pharmacological agents.
MβCD treatment had the most pronounced effect on the receptors,
with CD4 and CXCR4 being signiﬁcantly reduced and CCR5 surface
levels disappearing to almost undetectable levels. Cholesterol
replenishment restored the levels of CCR5 and CXCR4 to similar
levels as the untreated macrophages. Interestingly, CD4 expression
was decreased further by cholesterol replenishment to almost
undetectable levels. This complete knockdown in CD4 surface
expression may explain why only a partial restoration of HIV
reverse transcription was observed upon cholesterol replenishment
of MβCD treatment macrophages. The addition of cholesterol may
reduce CD4 expression to a level that is not favourable for HIV
infection. The mechanism by which cholesterol further decreases
CD4 surface expression is unknown but as these cholesterol-treated
macrophages have a more granular appearance by ﬂow cytometry,
we can speculate that these macrophages actively take up
cholesterol via an endocytic mechanism that may simultaneously
internalise CD4. It is not uncommon for cholesterol replenishment
to give rise to only partial restoration of infection; it has been
reported for other viruses with the suggested explanation being that
only one form of cholesterol may have been restored (Tang et al.,
2008).The reduction in surface expression of HIV receptors following
depletion of membrane cholesterol contrasts with ﬁndings using
different cells. Treatment with similar concentrations of MβCD caused
no reduction in plasma membrane expression of CD4 on primary T-
cells (Percherancier et al., 2003), PBLs (Viard et al., 2002) or PM1 T cell
line (Popik et al., 2002). The reduction of CD4 surface expression upon
MβCD and cholesterol treatment, to the best of our knowledge, seems
to be unique to macrophages. This observation may result from the
differences in CD4 expression and internalisation on macrophages
compared to T lymphocytes. In macrophages, CD4 expression levels
are 10 to 20-fold lower than they are in CD4+ T cells (Collman et al.,
1990; Kazazi et al., 1989; Lee et al., 1999), and CD4 internalisation rates
are enhanced, likely due to the absence of Lck (Pelchen-Matthews et
al., 1998). Reduction in CXCR4 and CCR5 surface expression has been
reported after treatment with a cyclodextrin derivative BCD in PM1
and primary T cells (Liao et al., 2001). More importantly, cholesterol
has been shown to be essential for the conformational integrity of
CCR5 and CXCR4, and in these studies BCD treatment prevented the
cell surface binding of antibodies speciﬁc for distinct CCR5 epitopes
(Nguyen and Taub, 2002a, 2002b). Molecular simulations, and work
with model membranes of deﬁned composition show that the
integrity of lipid raft microdomains is very sensitive to minor changes
in overall cholesterol concentrations (Risselada and Marrink, 2008).
Most likely, cholesterol depletion in macrophages disrupts lipid rafts,
thereby redistributing raft-associated proteins such as CCR5 to other
membrane domains. It is possible that, in this new context, their
conformation is altered to one that is no longer recognised by
antibodies, and unable to sustain HIV entry.
Nystatin and ﬁlipin complex modify cholesterol organisation
within cells, but do not affect overall cholesterol concentration, and
have a differing effect on HIV receptor levels. Nystatin signiﬁcantly
decreases CD4 and CCR5 surface expression but also signiﬁcantly
decreased non-raft associated CD71, implying that effect of nystatin
may not be restricted to proteins located in cholesterol rich domains.
Conversely, ﬁlipin complex treatment signiﬁcantly reduced CD4
expression levels and slightly decreased CCR5 levels but did not
appear to have such a dramatic effect on the expression of other
membrane proteins. The effects of cholesterol sequesteration on the
surface expression of the HIV receptors, after nystatin and ﬁlipin
treatment, have not been investigated before. Disruption of choles-
terol biosynthesis with Lovastatin also reduced the surface expression
of the HIV receptors on macrophages but not by signiﬁcant levels. This
is in contrast to observations with CD4 T lymphocytes, in which
Lovastatin down-modulated the mRNA and cell surface protein
expression of CCR5 (but not CD4 or CXCR4), resulting in reduced
HIV-1 infection (Nabatov et al., 2007).
The sensitivity of virus entry to depletion of cellular cholesterol
could be explained by the association of the viral receptors, CD4 and
CCR5, with lipid rafts. The tightly structured cholesterol-rich lipid
rafts, known as DRMs, can be isolated in the presence of ice cold 1%
Triton X-100 and separated by ultracentrifugation. Macrophage CD4
and CCR5 were found in the DRM fractions along with ﬂotillin-1
whose location in these membranes is well known. In contrast, CD71
was found in the soluble fractions reﬂecting its association with the
non-raft membranes. Decreased HIV receptor, but not CD71, expres-
sion after MβCD treatment supports the notion that the HIV receptors
are located in cholesterol-rich domains in macrophages. We provide
additional evidence for the involvement of lipid rafts in virus entry by
visualising virus uptake in parallel with a ﬂuorescent marker of lipid
rafts. At 20 min post infection, approximately a third of all cell-
associated virions were co-localised with lipid raft membranes in
punctate structures that appear to have been internalised and may
resemble an endosomal compartment.
CD4 associationwith DRMs has been established in many different
cell types and we can show this to be true for macrophage CD4 (Kozak
et al., 2002; Liao et al., 2001; Nguyen et al., 2005; Percherancier et al.,
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rafts in cell lines artiﬁcially over-expressing this receptor (Manes et al.,
1999; Popik et al., 2002), but not in primary CD4 T lymphocytes, where
this receptor was found in non-raft membrane domains (Percher-
ancier et al., 2003). Here, we show that in macrophages, CCR5 is also
present in or associated with lipid rafts, and both receptors required
for macrophage-tropic virus entry are localised in similar membrane
domains. This is in agreement with electron micrographs showing
CD4 and CCR5 (but not CXCR4) localised on the outer membranes of
microvilli and blebs in macrophages, often in closely apposed
microdomains (Singer et al., 2001). However, despite existing together
in DRMs it is possible that further aggregation of receptors is still
required and may occur upon gp120 binding.
The most likely explanation for the inhibition of productive HIV
entry into cholesterol-depleted macrophages is that redistribution of
(or conformational changes to) the HIV receptors render the
macrophages unsusceptible to HIV infection. It is plausible that
manipulation of membrane cholesterol may inhibit entry by other
mechanisms, of which we suggest ﬁve possibilities. 1) Depletion of
macrophage cholesterol may alter the lipid composition of the cellular
plasmamembrane so that it is no longer competent for fusionwith the
HIV lipid envelope. 2) Disruption of membrane rafts may prevent
receptor migration and co-localisation. Both CD4 and CCR5 are mobile
within cellular membranes (shown in CHO cells) with the chemokine
receptor being signiﬁcantly more mobile than CD4 and requiring
membrane cholesterol for this mobility (Steffens and Hope, 2004). 3)
Signal transduction pathways induced upon CCR5 and envelope
engagement may be required for virus entry (Harmon and Ratner,
2008). Cholesterol has been shown to be essential for CCR5 signalling
and its depletion may prevent these important signalling events in
macrophages (Cardaba et al., 2008). 4) HIV entry into macrophages
may proceed by macropinocytosis, and cholesterol-depletion may
block this uptake pathway in macrophages, as has been reported in
brain microvascular endothelia (Liu et al., 2002). 5) Lovastatin may
inhibit HIV entry by another mechanism, as it has been shown that
blockade of HMG CoA reductase impedes prenylation of small Rho
GTPases that may be involved in post-entry signalling events (del Real
et al., 2004), or by diminishing HIV-1 attachment to target cells by
suppressing ICAM1 LFA1 interactions (Giguere and Tremblay, 2004).
However, addressing these possibilities to determine the exact role of
cholesterol will be challenging, especially using infectious macro-
phage-tropic virus and primary macrophages. Our study highlights
the importance of cholesterol and lipid rafts in macrophage HIV
infection. This provides further support for the use of cholesterol
lowering pharmacological agents as anti-retroviral therapy by con-
ﬁrming their anti-viral effect in another pathogenically signiﬁcant HIV
target cell, the macrophage.
Materials and methods
Cell culture and virus stocks
Peripheral blood mononuclear cells (PBMCs) were isolated using
Ficoll-Paque Plus (GE Healthcare) density gradient centrifugation
from the blood of healthy donors. Monocytes were isolated by CD14
positive selection using anti-CD14 magnetic beads (Miltenyi Biotec)
according to the manufacturer's instructions. Monocytes were
seeded at a density of 1.5×105 cells/cm2 in 6-well plates, 12-well
plates, 24-well plates or T75 ﬂasks. Culture media referred to as
RPMI FCS M-CSF: consisted of RPMI 1640 (PAA) with 10% Fetal Calf
Serum (FCS; PAA), 2 mM L-glutamine (PAA), 100 U/mL penicillin and
100 μg/mL streptomycin (PAA), supplemented with 100 ng/mL
(approximately 1.7×104 U/mL) recombinant human M-CSF (R&D
Systems). Monocytes were differentiated for 7–9 days prior to use.
HIV-1 BaL was obtained through the AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH, from S. Gartner(Gartner et al., 1986) and viral stocks were generated in differen-
tiated, unstimulated PBMCs. Infected cell supernatants were har-
vested 14–21 days after infection and frozen for use in infectivity
assays. Virus stocks with proviral DNA removed were generated for
qPCR experiments by treatment with 100 μg/mL DNase I (Sigma). To
generate single round replication competent virus, 293T cells were
regularly passaged in DMEM (PAA) with 10% FCS, 2 mM L-glutamine,
100 U/mL penicillin and 100 μg/mL streptomycin. Cells seeded into
T75 ﬂasks were transfected with pNL4.3lucR-E- (2 μg) and pJRFL Env
(1.5 μg) using Fugene 6 according to manufacturers instructions. The
NL4.3 JRFL virus was harvested 48 h later, passed through a 0.44 μm
ﬁlter and frozen.
Treatment with cholesterol disrupting agents
Macrophages were washed once with serum-free RPMI, and
treated for 1 h at 37 °C with varying concentrations of MβCD, ﬁlipin
complex, or nystatin (all from Sigma) diluted in serum-free RPMI. As
Nystatin is dissolved in DMSO (MβCD and Filipin in water), to exclude
for any effects of this solvent the control cells were incubated in the
same dilution of DMSO as used for Nystatin. After incubation, cells
were washed once with serum-free RPMI prior to infection or ﬂow
cytometry analysis. Following infection, cells were cultured in RPMI
FCS M-CSF. Water soluble cholesterol (400 μg/mL, Sigma) was added
for a further 1 h where stated. For Lovastatin treatment, macrophages
were washed once with serum-free RPMI, before the addition of
varying concentrations of Lovastatin (Sigma) with or without
mevalonate (Sigma), diluted in RPMI with 10% lipoprotein-deﬁcient
serum (Sigma). Cells were left for 4 days at 37 °C before infection or
ﬂow cytometry analysis. Infected cells were cultured in RPMI FCS M-
CSF following the infection procedure.
Cell viability assays and cholesterol quantiﬁcation
To determine cell viability following treatment with cholesterol
disrupting agents, macrophages were incubated with CellTiter 96®
AQueous One Solution Cell Proliferation Assay reagent (Promega)
diluted 1/6 in serum-free RPMI or RPMI with lipoprotein-deﬁcient
serum containing Lovastatin or mevalonate, for 1 h at 37 °C. In
triplicate, 100 μL samples of the supernatant were then transferred to
a 96 well plate and the absorbance read at 490 nm. Background
absorbance readings from reagent and media alone were deducted
and the values expressed as a percentage of untreated cells. To
quantify cellular cholesterol levels, drug treated or control macro-
phages were detached by pipetting with PBS containing 5 mM EDTA
and 12 mM lidocaine (Sigma), on ice. Cells were lysed and the
cholesterol was extracted as previously described (Chung et al., 2005).
The amount of cholesterol was assayed with Amplex Red cholesterol
assay kit (Molecular Probes) according to the manufacturer's instruc-
tions and the concentrations were determined from a standard curve
and normalised to the number of cells.
Quantitative PCR
Macrophages were infected in 12-well plates with 500 μL of DNase
I treated HIV-1 BaL by spinoculation in a sealed plate spinning
centrifuge at 2000 ×g for 90 min at 37 °C. The virus inoculum was
removed, cells were overlaid with RPMI FCS M-CSF and infections
were left to proceed for 28–30 h. Cells were harvested by scraping and
DNA was extracted using DNeasy Blood and Tissue Kit (Qiagen)
according to the manufacturer's instructions. qPCR reactions to detect
late stage reverse transcription products were carried out as
previously described (Butler et al., 2001; Cohen et al., 2008). HIV-1
standards consisting of pNL4.3LucR-E- HIV-1 backbone plasmid
diluted with 30 ng/μL HeLa DNA were used in duplicate at dilutions
ranging from 10 to 1×107 copies, and actin standards consisting of
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ELISA for p24 antigen
To measure multiple rounds of HIV infection, macrophages were
infected in 12-well plates with HIV-1 BaL for 2 h at 37 °C. The
inoculum was removed and replaced with RPMI FCS M-CSF. Over a
14–16 day period, supernatant samples were taken at intervals and
kept at −80 °C. For analysis of HIV-1 binding, macrophages were
incubated with HIV BaL for 2 h on ice. The cells were then washed 5
times in ice-cold PBS to remove unbound virus, and lysed in 200 μL
TES (1×Tris buffered saline [TBS], 1% Empigen [Fluka], 10% FCS, 0.05%
Tween 20) before heat inactivation. For analysis of HIV-1 production,
samples from infected cells were diluted in TES and heat inactivated.
To create a standard curve, recombinant p24 protein (Aalto) was
diluted in doubling dilutions in TES. Costar EIA/RIA ﬂat bottom high
binding 96-well plates (Corning) were pre-coated with 10 μg/mL
sheep anti-HIV-1-p24 Gag antibody (clone D7320, Aalto) diluted in
0.05 M carbonate-bicarbonate buffer pH 9.6 (Sigma) and blocked
with 2% BSA (Sigma) in TES. Diluted samples or standards were
added to the plates and after overnight incubation at room
temperature, bound p24 was detected using a biotinylated mouse
anti-HIV-1-p24 Gag antibody (clone EH12EI, Centre for AIDS
reagents, NIBSC) at 0.23 μg/mL in TT/SS (TBS, 20% FCS, 0.05% Tween
20) followed by 0.625 μg/mL streptavidin-HRP (Pierce). Plates were
developed using TMB substrate (Pierce), the reaction was stopped
with 1 M H2SO4 (Sigma) and plates were then read using a Molecular
Devices E max precision microplate reader and SoftMax Pro software
version 4.0. GraphPad Prism software version 4 was used to create
standard curves (2-site binding equation) and to calculate unknown
values.
Antibody staining and ﬂow cytometry
Detached macrophages were washed once with FACS buffer (PBS,
0.01% NaN3, 1% FCS, 10 μg/mL human IgG), and 1×105 cells were
incubated with 5 μg/mL directly conjugated mouse anti-human
antibodies to CD4 (clone 1180), CCR5 (clone 45531), CXCR4 (clone
44717.111) or appropriate isotype control (all R & D systems). As a
control, the expression of the non-raft associated protein transferrin
receptor was also measured using mouse anti-human CD71 (clone
RVS10) with isotype control mouse IgG1 (clone 203) (both diluted 1/
10 and from Immunotools). Cells were ﬁxed in 4% formaldehyde. Flow
cytometry was carried out using a Becton-Dickinson FACSCalibur ﬂow
cytometer with 10000 events collected and data analysed using
FlowJo software, version 7.1.3.
Cholera toxin B binding
Macrophages were washed once in serum-free RPMI, and
incubated with CTB-FITC (Sigma) at 10 μg/mL in serum-free RPMI,
for 30 min on ice or at 37 °C. Detached cells were then analysed by
ﬂow cytometry as described. To visualise virus and CTB, HIV-1 capable
of a single round of infection NL4.3 JRFL was spinoculated (1 h at 4 °C
at 700 ×g) onto day 7 macrophage monolayers seeded onto glass
coverslips in 24 well plates. Cells were washed with ice-cold PBS and
incubated in RPMI containing 10 μg/mL CTB-FITC for 20 min at 37 °C.
Cells were ﬁxed in 4% formaldehyde, quenched in 80 mM glycine in
PBS and permeabilised in buffer containing 1% FCS, 0.1% saponin and
human IgG 10 μg/mL in PBS. To detect virus, cells were stained with
mouse anti-HIV p17 diluted 1/500 (clone 4C9, Centre for AIDS
Reagents, NIBSC) followed by Alexa Fluor 647 conjugated goat anti-
mouse IgG2a antibody diluted 1/400 (clone A21131, Invitrogen).
Coverslips weremounted on slides usingmowiol and images collected
using a Zeiss Pascal Microscope.Membrane fractionation and western blotting
Macrophages (1×107) were harvested by scraping, pelleted and
suspended in 1 mL H buffer (10 mM sodium Hepes, pH 7.2, 250 mM
sucrose, 2 mM MgCl2, 10 mM NaF, and 1 mM vanadate) containing
protease inhibitors (Roche). The cells were nitrogen-cavitated using a
nitrogen cavitation bomb (model 4639; Parr Instrument Company)
equilibrated at 4 °C, 50 bar for 10 min (Harder and Kuhn, 2000). Cells
were further disrupted by adding 1 mL HNE buffer (10 mM Hepes, pH
7.0, 150 mM NaCl, and 5 mM EDTA), passaged 15 times through a 23G
syringe and 1% Triton X-100 was added before cells were incubated
for 1 h at 4 °C. A 200 μL extract containing approximately 1×106 cells
was adjusted to 45% Optiprep™ (Nycomed Pharma) and transferred
to an SW55 centrifuge tube (Beckman Coulter) and overlaid with
another 200 μL 45% Optiprep to make a 1 mL layer. This was overlaid
with 2 mL of 35% and 0% Optiprep in HNE and gradients were spun at
40,000 rpm for 3 h at 4 °C. Nine fractions of 550 μL were collected and
precipitated in an equal vol of 20% trichloroacetic acid, washed twice
in ice-cold acetone and resuspended in 8 M urea and SDS sample
buffer. Equal volumes of each fraction were run on a 10% SDS-PAGE
protein gel with Biorad precision plus protein standards. Protein was
transferred onto 0.2 μm PVDF membranes, and membranes were
incubated with primary mouse anti-human antibodies to CD4 (clone
34915, 2.5 μg/mL R & D systems) CCR5 (clone CTC5, 2.5 μg/mL R & D
systems), ﬂotillin-1 (clone 18, 1.25 μg/mL, BD biosciences) and
transferrin receptor (clone 2, 1.25 μg/mL, BD biosciences). To detect
primary antibody binding, membranes were incubated with goat anti-
mouse IgG (Fab speciﬁc) antibody conjugated to alkaline phosphatase
(Sigma) diluted 1/30,000. Protein was detected using ECF substrate
(Pierce), and membranes were imaged using STORM imager.
Statistical analysis
Statistical analysis was performed by two-tailed paired t-test
(unpaired with 2 replicates) using GraphPad Prism version 4. Stars
indicate the p value: ⁎=signiﬁcant p=0.05–0.01, ⁎⁎=very signiﬁcant
p=0.01–0.001, ⁎⁎⁎=extremely signiﬁcant pb0.001.
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